2019

December 5, 2019
Apogenix to Present New Data on Asunercept at ESMO Immuno-Oncology Congress

November 7, 2019
Strong Quality of Life Data for Apogenix’ Asunercept Published in Journal of Neuro-Oncology

October 10, 2019
Apogenix to Present at Several Upcoming International Conferences

September 24, 2019
ESMO and Apogenix Collaborate on “Recurrent Glioblastoma Management: Challenges and Opportunities” Colloquium

September 19, 2019
Publication in Human Vaccines & Immunotherapeutics Illustrates the Advantages of Hexavalent CD40 Agonists in Targeting CD40 in Immuno-Oncology

September 2, 2019
Publication in Cancer Management and Research Underlines the Potential of Apogenix’ Asunercept for the Treatment of Other Malignancies Beyond Glioblastoma and MDS

July 23, 2019
Excellent Preclinical Efficacy Data of Apogenix’ HERA-GITRL Published in Journal for ImmunoTherapy of Cancer

May 7, 2019
Apogenix to Present at Four Upcoming International Conferences

March 7, 2019
Apogenix Announces Oral and Poster Presentations at Upcoming International Conferences
 

2018

October 18, 2018
Apogenix to Present at Five Upcoming International Conferences

October 11, 2018
Preclinical Efficacy Data of Apogenix’ HERA-CD40L Published in Journal of Immunotherapy

October 2, 2018
Preclinical Efficacy Data of Apogenix’ HERA-CD27L Published in Frontiers in Oncology

August 1, 2018
Apogenix Strengthens Patent Position for Lead Drug Candidate Asunercept

May 23, 2018
Apogenix Provides Update on Clinical Development of Asunercept

2017

October 5, 2017

Apogenix Granted Orphan Designation by the European Commission for Asunercept to Treat Myelodysplastic Syndromes

May 29, 2017
Apogenix Granted PRIME Designation by European Medicines Agency for Asunercept to Treat Glioblastoma

April 26, 2017
Apogenix to Present at Three Upcoming International Conferences

April 11, 2017
Apogenix Announces Initiation of Clinical Development for ABBV-621 to Treat Solid and Hematologic Tumors by Partner AbbVie

March 20, 2017
Apogenix Presents Data on Novel Hexavalent TNF Receptor Agonists (HERA-Ligands) at the Upcoming Annual Meeting of the American Association for Cancer Research (AACR)


For press releases from previous years, please visit our archive.